Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-09-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving a drug registration certificate from the national drug regulatory authority. It details the certificate information, product description, and potential impact on the company. The document is short (1127 characters) and does not contain financial statements or detailed financial data. It is an official announcement of a regulatory approval event, not a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company event that does not fit other specific categories.
2024-09-18 Chinese
2024年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as a "2024年半年度权益分派实施公告" which translates to "2024 Half-Year Dividend Distribution Implementation Announcement." It details the dividend distribution plan approved at a shareholders' meeting, including the dividend amount, record date, ex-dividend date, and the method of dividend payment. The document is an announcement of the implementation of a dividend distribution, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on dividend payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short (1674 characters), consistent with an announcement rather than a full report.
2024-09-13 Chinese
关于回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a share repurchase and cancellation of shares by the company 亿帆医药股份有限公司. It details the number of shares repurchased and cancelled, changes in total share capital, and the impact on the company. The text references specific repurchase plans, board approvals, and regulatory compliance but does not contain financial statements or detailed financial performance data. The document is focused on the company's own shares being bought back and cancelled, which fits the category of a Transaction in Own Shares (POS). The document length is 2578 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is POS with high confidence.
2024-09-10 Chinese
关于变更回购股份用途并注销暨通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from 亿帆医药股份有限公司 regarding the change in the purpose of repurchased shares and their subsequent cancellation, along with a notification to creditors about the reduction in registered capital. It details the board and shareholder meeting approvals, the number of shares to be cancelled, and the legal notification process to creditors. The content focuses on share repurchase usage change and share cancellation, which is a capital structure change. The document is relatively short (1484 characters) and is a formal announcement rather than a detailed financial report or analysis. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company announcements about share buybacks and cancellations.
2024-09-03 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of 亿帆医药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders during the meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or investor presentation. The document is not merely announcing the publication of a report but is itself the official declaration of voting results from a shareholders meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3066 characters, which is consistent with a detailed voting results announcement rather than a full report.
2024-09-03 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2024年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2024 first extraordinary general meeting (临时股东大会) of Yifan Pharmaceutical Co., Ltd. It details the legal compliance of the meeting's call, attendance, voting procedures, and the validity of resolutions passed. It does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results but a legal opinion on the meeting's legality and procedures. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal document related to corporate governance and shareholder meetings but does not fit the more specific categories like AGM Information or Declaration of Voting Results, which would require actual voting results or meeting materials. The document length is 3022 characters, relatively short, and it is a legal opinion letter, not a report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-03 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.